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Adenosine is a purine nucleoside that acts as a regulatory molecule by binding to specific G-protein-coupled A1, A2A,A 2B, and A3 cell
surface receptors. We have recently demonstrated that adenosine inhibits tumour cell growth and concomitantly stimulates bone
marrow cell proliferation via activation of the A3 adenosine receptor (A3AR). In the present study, we show that a synthetic agonist
to the A3AR, CF101, at the low nanomolar concentration range, inhibits HCT-116 human colon carcinoma cell growth. This effect
was reversed by the selective A3AR antagonist MRS1523, demonstrating the specificity of the response. CF101 (given orally) was
efficacious in inhibiting the development of primary tumours in xenograft and syngeneic models in which mice were inoculated
subcutaneously with human HCT-116 or murine CT-26 colon carcinoma cells, respectively. Moreover, CF101 suppressed (50%,
Po0.01) colon cancer liver metastases in syngeneic mice inoculated to the spleen with CT-26 cells. The mechanism of action entailed
upregulation of interleukin-12 production in the CF101-treated groups and potentiation of NK cell activity. In the HCT-116 xenograft
model in which a combined therapy of CF101 and 5-fluorouracyl (5-FU) was examined, an additive antitumour effect was
demonstrated. Moreover, CF101 prevented the 5-FU-induced myelotoxicity, resulting in normal values of white blood cell and
neutrophil counts. We conclude that the A3AR agonist CF101, a small orally bioavailable molecule, exerts systemic anticancer,
antimetastatic, and myeloprotective effects in colon carcinoma-bearing mice, and may serve as an adjuvant treatment to enhance the
chemotherapeutic index and prevent myelotoxicity.
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The realisation that the A3 adenosine receptor (A3AR) may be a
new target for cancer therapy is a result of a research that has its
roots in a well-recognised clinical phenomenon, that is, the rarity
of tumour metastases in striated muscle tissue. It was found that
muscle cells secrete small molecules, which inhibit growth of a
broad range of different tumour cell lines in vitro, such as
melanoma, carcinoma, leukemia, and lymphoma (Djaldetti et al,
1996; Bar-Yehuda et al, 1999). Remarkably, these small molecules
induced proliferation of normal cells, such as bone marrow,
fibroblasts, and muscle cells. When administered orally to
melanoma-bearing mice, these small molecules inhibited the
development of lung metastases. Moreover, when given in
combination with cyclophosphamide, the molecules enhanced
the chemotherapeutic index and induced a myeloprotective effect.
Thus, the muscle-derived small molecules show a dual activity
entailing inhibition of tumour and stimulation of normal cell
growth.
Adenosine was shown to be among those small, muscle-secreted
molecules. It is a ubiquitous nucleoside, which is released into the
extra cellular environment of metabolically active cells, and was
shown, in vitro, to possess the aforementioned dual activity
(Fishman et al, 1998). Adenosine binds to cells through specific
A1, A2A,A 2B, and A3 G-protein-associated cell surface receptors,
thus acting as a signal transduction molecule by regulating the
levels of cAMP and the downstream effector protein kinase A
(Stiles, 1990; Linden, 1991). However, oral administration of
adenosine to mice did not generate an effect similar to that
observed with the muscle-derived small molecules, hence endor-
sing further research to explore the active component. Pharma-
cological studies, using antagonists to the different adenosine
receptors, revealed that A3AR plays a key role in the adenosine-
induced inhibition of tumour cell proliferation, simultaneously
stimulating bone marrow cell growth (Fishman et al, 2000a,b; Bar-
Yehuda et al, 2001). Indeed, synthetic agonists to A3AR, such as
CF101 and Cl-IB-MECA (Jacobson et al, 1995), were found to act
similar to adenosine, while having the advantage of being stable,
nondegradable, and bioavailable molecules (Fishman et al,
2000a,b).
Notably, the differential effect exerted by the A3AR agonists
occurred specifically at the nanomolar concentration range, in
which exclusive activation of A3AR took place (Fishman et al,
2000b, 2001). The mechanism involved in the inhibition of tumour
cell growth included a cytostatic effect leading to cell cycle arrest in
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sthe G0/G1 phase of the cell cycle. It was further shown that
deregulation of the Wnt signalling pathway is involved in the
anticancer effect exerted by A3AR agonists (Fishman et al, 2002,
2003), hence identifying a potential role for these agonists in the
treatment of colon malignancy.
Chemotherapy after primary surgery is recommended for
patients with colon carcinoma and nodal involvement to reduce
the rate of cancer recurrence and prolong survival. Current
therapy is far from being uniformly useful to patients and not
without side effects, thus limiting the appropriate dosage and
duration of chemotherapy. The stimulatory effect of CF101 on
bone marrow cell proliferation was mediated via the induction of
G-CSF production (Fishman et al, 2000a, 2001; Bar-Yehuda et al,
2002). Thus, it became apparent that the A3AR might serve as a
target for anticancer and myeloprotective treatments.
Natural cytotoxicity, mediated by NK cells, is believed to play an
important role in host anticancer mechanisms. In the colon,
neoplastic lesions were found to exist where NK activity
was inhibited, while under the influence of normal NK cells, these
lesions remained dormant (nonproliferative) (Altmann, 1995).
Interleukin-12 (IL-12), previously designated NK cell stimulatory
factor (NKSF), is released from antigen-stimulated monocytes,
macrophages, and lymphocytes, and mediates several bio-
logical activities of T and NK cells, including the induction
of INF-g production and enhancement of cell-mediated
cytotoxicity (Trinchieri, 1993; Lee et al, 1998). IL-12 has been
shown to possess anticancer activity in a wide variety of murine
tumour models, including carcinoma of the colon (Smyth et al,
2000).
In this study we further show that CF101, an A3AR agonist,
inhibits the growth of colon carcinoma cells both in vitro and in
vivo, and that in addition to the direct antiproliferative effect an
immunomodulatory mechanism is involved.
MATERIALS AND METHODS
Drugs
The A3AR agonist known generically as 1-deoxy-1-amino]-9H-
purine-9-yl]-N-methyl-(-D-ribofuranuronamide) (CF101), a GMP
grade, was synthesised for Can-Fite BioPharma by Albany
Molecular Research Inc., Albany, NY, USA (molecular structure
is presented in Figure 1). The A3AR antagonist MRS1523 was
purchased from RBI/Sigma. For both reagents, a stock solution of
10mM was prepared in DMSO and further dilutions in RPMI
medium were performed. RPMI, fetal bovine serum (FBS), and
antibiotics for cell cultures were purchased from Beit Haemek,
Haifa, Israel. The primary antibodies included rabbit polyclonal
against murine and human A3AR and the secondary antibodies
included anti-rabbit and anti-Goat, respectively, and were
purchased from Santa Cruz Biotechnology Inc., CA, USA and
served as primary antibodies.
The chemotherapy agent 5 fluorouracil (5-FU) was purchased
from ABIC (Israel).
Tumour cells
HCT-116 human and CT-26 murine colon carcinoma cells were
purchased from the American Type Tissue Culture Collection
(ATCC, Rockville, MD, USA). Cells were maintained in RPMI
medium supplemented with 10% FBS, 200mM glutamine,
100Uml
 1 penicillin, and 100mgml
 1 streptomycin. Cells were
transferred to a freshly prepared medium twice weekly. For studies
in which we used serum-starved cells, FBS was omitted from the
cultures for 18h and the experiment was carried out on
monolayers of cells in RPMI medium supplemented with 1% FBS
in a 371C, 5% CO2 incubator.
Examination of A3AR protein expression in colon
carcinoma cells by Western Blot (WB) analysis
To detect the protein expression level of A3AR, HCT-116 human
colon carcinoma or CT-26 murine cells (5 10
4ml
 1) were
incubated in the presence and absence of CF101 (10nM) for
15min at 371C with 1% FBS. Cell samples were rinsed with ice-cold
PBS and transferred to ice-cold lysis buffer (TNN buffer, 50mM
Tris buffer pH 7.5, 150mM NaCl, NP-40). The trypsinised cells
were washed again with ice-cold PBS, harvested by centrifugation,
and subjected to lysis in TNN buffer. Cell debris was removed by
centrifugation for 10min, at 7500g. The supernatant was utilised
for WB analysis. Protein concentrations were determined using the
Bio-Rad protein assay dye reagent. Equal amounts of the sample
(50mg) were separated by SDS–PAGE, using 12% polyacrylamide
gels. The resolved proteins were then electroblotted onto
nitrocellulose membranes (Schleicher & Schuell, Keene, NH,
USA). Membranes were blocked with 1% bovine serum albumin
and incubated with the relevant primary antibody (dilution
1:1000) for 24h at 41C. Blots were then washed and incubated
with the secondary antibody for 1h at room temperature. Bands
were recorded using BCIP/NBT color development kit (Promega,
Madison,W1, USA). Data presented in the figure are representative
of at least four different experiments.
Cell proliferation assay
[
3H]thymidine incorporation assay was used to evaluate cell
growth. HCT-116 colon carcinoma cells (5 10
4ml
 1) were
incubated with CF101 at a concentration of 0.1, 1, and 10mM,i n
96-well microtitre plates for 24h. To test whether CF101 exerted its
effect on tumour cells through specific binding to the A3AR,
MRS1523 (0.1mM), an antagonist to the A3AR, was added to the
cell cultures 30min prior to CF101 introduction. Cultures of HCT-
116 cells that were incubated in the presence of MRS-1523 only,
served as controls. For the last 18h of incubation, each well was
pulsed with 1mCi [
3H]thymidine. Cells were harvested and the
[
3H]thymidine uptake was determined in an LKB liquid scintilla-
tion counter (LKB, Piscataway, NJ, USA). These experiments were
repeated at least four times.
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Figure 1 Chemical structure of the synthetic A3AR agonist 1-deoxy-1-
[6-[[(iodophenyl)methyl]amino]9H-purine-9-yl]-N-methyl-(-D-ribofuranur-
onamide), CF101.
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sIn vivo studies
All the experiments were performed in accordance with the
guidelines established by UKCCCR guidelines (Workman et al,
1998) and the Institutional Animal Care and Use Committee at the
Rabin Medical Center, Petach Tiqva, Israel.
In this set of experiments, we tested the effect of CF101 on the
growth of human HCT-116 and murine CT-26 colon carcinoma
cells. For the HCT-116 model, cells (1.2 10
6) were subcuta-
neously injected to the flank of Nude/BalbC mice. Mice were
divided into four groups and treatment was initiated 1 day after
tumour inoculation. Each group contained 10 mice and the
experiment was repeated three times.
CF101 dose was chosen based on the PK analysis after oral
administration of CF101 to mice and the assumption that
absorption of the drug is linearly related to the administered
dose. A dose of 10mgkg
 1 yielded a maximal drug concentration
of about 4nM, in which all receptors are expected to be bound with
the drug (Ki¼0.4nM) (unpublished data).
The following protocol was utilised:
1. control group – vehicle only.
2. 10mgkg
 1 body weight CF101, given orally once daily (initiated
7 days after tumour inoculation),
3. chemotherapy – one cycle of intraperitoneal 5-FU at
20mgkg
 1, given once a day for five consecutive days (initiated
1 day after tumour inoculation),
4. 5-FUþ10mgkg
 1 body weight CF101 (as detailed above).
Tumour size (width (W) and length (L)) was measured every 4
days and was calculated according to the following formula:
tumoursize ¼
ðWÞ
2 L
2
We further compared the response of each treatment vs control by
calculating the percentage of tumour growth inhibition, at each
time point, according to the following formula:
1  
tumoursizein thetreatedgroup
tumoursizein thecontrolgroup
 100
The study was terminated when tumour size in the CF101-
treated group reached the EC50.
To test the myeloprotective effect of CF101, blood samples were
withdrawn 48h after the initiation of CF101 treatment.
For the CT-26 primary colon carcinoma model, cells (1x10
6)
were subcutaneously injected to the flank of syngeneic Balb/C
mice. Treatment was initiated 1 day after tumour inoculation and
mice were killed after 15 days.
For the CT-26 liver metastasis model, syngeneic Balb/C mice
were anaesthetised with ketamine (22 mgkg
 1) and xylazine
(10 mgkg
 1). After prepping with betadine, left upper quadrant
laparotomy and splenic exteriorisation were performed. Using a
27-gauge needle, 50ml of the tumour cell suspension (0.5 10
6
cellsml
 1 PBS) was injected beneath the splenic capsule. The
spleen was returned to the peritoneal cavity followed by two-layer
closure of the peritoneum and skin using 6-0 nylon sutures. The
mice were treated daily orally with 10mgkg
 1 CF101 or the vehicle
(each group contained 10 mice and the experiment was repeated
three times). Treatment was initiated 1 day after tumour
inoculation and mice were killed after 12 days. Liver metastasis
was evaluated by a score ranging from 0 to 4, based on metastasis
load.
Blood cell counts
White blood cell (WBC) counts were carried out in a Coulter
counter and differential cell counts were performed on smear
preparations stained with May–Grunvald–Giemsa solution.
Ex vivo NK activity
To test NK cell activity of splenocytes derived from CF101- and
vehicle-treated HCT-116 tumour-bearing mice, the standard 4h
release assay was used. YAC lymphoma cells served as targets.
Splenocytes (1 10
6) were cultured in 96-well plates and
resuspended in RPMI containing 10% FBS. The YAC lymphoma
cells were labelled with 100mCi of Na2O4 at 371C for 1h. cells
(2 10
4) were then resuspended and mixed with the effector cells
at an E:T ratio of 50:1, in a volume of 200ml. After 4h of
incubation at 371Ci n5 %C O 2, plates were centrifuged and
supernatants were counted in a gamma counter (LKB). NK
cytotoxicity was calculated using the following equation:
%lysis ¼
CPMexperiment   CPMspontaneous
CPMmaximal   CPMspontaneous
 100
Spontaneous and maximal counts per minute (CPM) were
determined by measuring the supernatant’s CPM of target cells
(alone or in the presence of 1% SDS). The spontaneous release was
below 10% of the maximal release throughout the experiments.
IL-12 analysis in serum sapmles
Serum samples for IL-12 analysis were obtained from HCT-116
tumour-bearing mice previously treated or untreated with the drug
and assayed by a commercial murine ELISA kit of R&D systems,
Minneapolis, MN, USA.
Statistical analysis
The efficacy of the various agents in vitro and in vivo was
evaluated using the Student’s t-test. The criterion for statistical
significance was Po0.05.
RESULTS
A3AR expression in HCT-116 and CT-26 colon carcinoma
cells
A3AR was highly expressed in HCT-116 and CT-26 cells. Upon
treatment with CF101, the receptor level was downregulated
indicating the cell response to the agonist. The level of expression
was quantified based on a comparison to the housekeeping gene b-
actin (Figure 2).
CF101 inhibits cell proliferation in vitro
CF101 exerted a dose-dependent inhibitory effect on the growth of
HCT-116 cells in vitro, at the nanomolar and micromolar
concentration range (Po0.002, for all concentrations). The
A3AR antagonist MRS1523 counteracted most of the inhibitory
effect of CF101 at the nanomolar concentrations (Po0.001, for all
the concentrations), whereas at the 10mM concentration, the
inhibitory effect was not fully blocked by the antagonist (CF101 vs
MRS1523, Po0.05) (Figure 3). In an additional set of experiments,
we tested the effect of higher CF101 dosages on the proliferation of
HCT-116 cells. EC50 was detected at a drug concentration of 30mM;
however, this effect was not counteracted by MRS1523. These
results demonstrate that at low CF101 concentrations, the response
is exclusively A3AR mediated. However, at the micromolar range,
additional adenosine receptors may be activated, which are
responsible for the tumour growth proliferation inhibition.
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liver metastasis in vivo
In these experiments, we evaluated the inhibitory effect of CF101,
given as a monotherapy or in combination with 5-FU, to inhibit
the growth of flank human HCT-116 colon carcinoma tumours.
Tumour size was markedly inhibited following treatment with
CF101 or 5-FU (Po0.0001 and o0.0001, respectively), and the
combined therapy yielded an additive effect (Po0.0001) (Figure 4).
Table 1. summarises the percentage of tumour size inhibition at
various time points, demonstrating that tumour growth inhibition
in the combined treatment yielded the maximal effect. We further
evaluated the inhibitory effect of CF101 on the development of
primary and liver metastasis in mice inoculated with CT-26 murine
colon carcinoma cells. A marked inhibition in the development of
the flank tumours (Po0.01) and liver metastasis (Po0.01) was
observed in the CF101-treated mice (Figure 5).
CF101 acts as a myeloprotective agent
Mice treated with 5-FU exhibited a decline in the number of
peripheral blood leucocytes and absolute neutrophil counts (ANC).
Administration of CF101 following chemotherapy increased the
number of WBC (Figure 6A) and restored the percentage of
neutrophils (Po0.001 and o0.01, respectively) (Figure 6B).
CF101 acts as an immunomodulatory agent
To test whether the inhibitory activity of CF101 is also mediated by
an indirect immunomodulatory effect, we tested IL-12 serum level
and NK cell activity in the HCT-116 tumour-bearing mice. CF101
treatment elevated IL-12 serum level and potentiated NK cell
activity (Po0.05 for both) (Figure 7A,B).
DISCUSSION
This study shows that orally administered CF101, an A3AR
agonist, possesses anticancer activity against HCT-116 human and
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colon carcinoma cells. Cells (5 10
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 1) were incubated for 15min at
371C with and without 10nM CF101. High A3AR expression level is seen in
the control vs downregulation of receptor expression, indicating that
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Figure 3 CF101 inhibits the proliferation of HCT-116 human colon
carcinoma cells in vitro. Cell proliferation was measured by the
[
3H]thymidine incorporation assay. The introduction of MRS1523 counter-
acted most of the inhibitory effect that was exerted by CF101.
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Figure 4 Effect of CF101 alone or in combination with 5-FU on the
growth of HCT-116 human colon carcinoma cells in nude mice. Tumour
cells (1.2 10
6) were subcutaneously injected to the flank of nude mice.
The following treatment modalities were applied: 5-FU (20 mgkg
 1, given
once a day for 5 days, initiated 1 day after tumour inoculation); 10mgkg
 1
CF101 daily orally, initiated 7 days after tumour inoculation; combination of
5-FU and CF101 as detailed above for each treatment alone and vehicle.
Tumour size was measured every 4 days.
Table 1 % of tumour size inhibition at various time points
Day 5-FU CF101 CF101+5-FU
10 95.27 81.21 92.95
13 86.06 86.9 87.86
15 77.57 88.42 87.86
20 72.85 65.53 82.09
23 62.27 56.49 78.26
27 43.75 63.79 78.02
29 33.77 52.55 73.43
Effect of CF101 alone or in combination with 5-FU on the growth of HCT-116
human colon carcinoma cells in nude mice. Tumour cells (1.2 10
6) were
subcutaneously injected to the flank of nude mice. The following treatment
modalities were applied: 5-FU (20mgkg
 1, given once a day for 5 days, initiated 1 day
after tumour inoculation), 10mgkg
 1 CF101 daily orally, initiated 7 days after tumour
inoculation, combination of 5-FU and CF101, as detailed above for each treatment
alone and vehicle. Tumour size was measured every 4 days.
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against chemotherapy-induced myelotoxicity.
CF101 exerted in vitro a dose-dependent inhibitory effect on the
growth of HCT-116 human colon carcinoma cells at the low mM
concentration range. The MRS1523 antagonist reversed this
inhibitory effect at the low micromolar concentrations, demon-
strating that the inhibitory effect of CF101 was A3AR mediated. At
the higher concentration (10mM) the activity of CF101 was only
partially counteracted by MRS1523, while at 100mM there was no
effect of the antagonist on the level of the growth inhibition
induced by the CF101, demonstrating that additional adenosine
receptor may be involved in the response.
We thus concluded to utilise in vivo only low concentrations of
CF101, in order to test exclusively the effect on A3AR activation.
Oral administration of CF101 to nude mice resulted in the
inhibition of HCT-116 human colon carcinoma growth. Moreover,
an additive inhibitory effect was observed when CF101 was
administered in combination with 5-FU. The efficacy of CF101 in
vivo was demonstrated in additional primary and metastatic colon
carcinoma models. CF101 suppressed the development of the
primary tumour and the liver metastases of colon carcinoma CT-
26 cells. It is suggested that CF101 effect is tumour nonspecific and
that a general systemic mechanism is induced. Indeed, in this
study, we show that CF101 increased IL-12 production and
potentiated the activity of NK cells. Splenocytes obtained from
mice treated orally with CF101 exhibited an increased NK cell
activity when incubated ex vivo with target cells. It is well
established that NK cells play a role in the regulation of tumour
growth (Miller, 2001) and that the activation of endogenous NK
cells in a tumour-bearing host may be therapeutically beneficial.
Dibutyryl cAMP or forskolin (both activate adenylyl cyclase and
elevate cAMP level in cells) was reported to inhibit the cytolytic
activity of NK cells against certain tumour target cells (Hall et al,
1983). Activation of the A3AR, which inhibits adenylyl cyclase
activity and decreases cAMP levels, may thus lead to the activation
of NK cells.
Link et al (2000) showed that a specific A2a receptor agonist
inhibited the production of IL-12 in whole blood and monocyte
cultures. In addition, in vivo studies by Hasko et al (1998) in
BALB/c mice, pretreated intraperitonealy with IB-MECA (0.2–
0.5 mgkg
 1), demonstrated a decrease in the lipopolysaccharide-
induced plasma levels of interleukin-12 and interferon-gamma. It
is suggested that high CF101 doses may activate the A2A receptor
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Figure 5 Effect of CF101 on the development of primary tumour and
liver metastasis in CT-26 colon carcinoma-bearing mice. For the primary
tumour model CT-26 cells were subcutaneously injected to the flank of
nude mice, and for the liver metastatic model CT-26 cells were injected
beneath the spleen capsule. For both models, treatment was initiated 1 day
after tumour cell inoculation and included daily oral administration of
CF101 (10mgkg
 1) till the mice were killed.
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Figure 6 In vivo effect of CF101 on the number of WBC and ANC in
mice treated with 5-FU (20 mgkg
 1, given once a day for 5 days).
Chemotherapy alone decreased the number of WBC and ANC of
neutrophils. CF101, administered orally after chemotherapy, increased the
number of WBC (A) and percentage of neutrophils (B) to almost normal
values.
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in this study, exclusively activate the A3AR and will results in IL-12
upregulation and potentiation of NK cell activity.
In the present study, CF101, in vivo, counteracted the
myelotoxicity induced with 5-FU by increasing the number of
WBCs and neutrophils. Based on our previous data, we suggest
that the chemoprotective effect of CF101 was mediated by the
induction of G-CSF production (Fishman et al, 2001b). G-CSF is
clinically used to reduce the length of neutropenia following
chemotherapy and bone marrow transplantation. It stimulates the
proliferation and differentiation of hematopoietic progenitors and
also controls the functional activities of neutrophils and macro-
phages (Ikebuchi et al, 1988; Itoh et al, 1992). Our results are
supported by those of Pospisil et al (1993, 1995, 1998), who showed
that administration of adenosine monophosphate (AMP) com-
bined with dypyridamole and G-CSF, prior to radiation, led to a
radioprotective effect by the stimulation of haematopoiesis in the
bone marrow and spleen of treated mice. The chemoprotective
feature of the A3AR agonists is associated with other cytoprotec-
tive characteristics of these compounds. A3AR activation by low
agonist concentration has been found to mediate functions, such
as cerebroprotective activity following chronic administration of
IB-MECA to gerbils with cerebral ischaemia (von Lubitz et al,
1994), cardioprotective activity during prolonged stimulated
ischaemia by rescuing injured myocytes (Liu et al, 1994), and an
anti-inflammatory effect (Bowlin et al, 1997).
Taken together, activation of the A3AR induces a dual effect in
colon carcinoma-bearing mice, that is, the induction of anticancer
activity concomitantly with a myeloprotective effect. The antic-
ancer activity was shown to be attributed to direct antiproliferative
effect and to an indirect effect manifested by upregulation of IL-12
and NK cell activity. The above-mentioned unique properties of
CF101 suggest a potential role for the A3AR agonists in the combat
of colon cancer.
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